Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Soligenix has specialized expertise in the development of orphan and unmet medical need indications – including the regulatory nuances (Orphan Drug designation, Fast Track designation, use of adaptive trial designs etc.) and clinical execution (specialized recruitment approaches, direct site interactions etc.). Soligenix directly conducts all of its Phase 2 and 3 clinical studies, being in personal contact with the sites and principal investigators, ensuring the highest data quality while streamlining timelines and budgets.
Three reasons to invest in Soligenix Inc.
A passionate management team: Experienced in successfully bringing new drugs to market in the rare disease setting.
A rare disease pipeline funded by the United States government: Allowing us to manage our cash burn very effectively.
Multiple key clinical inflection points in 2019 and early 2020: Phase 3 clinical programs in Cutaneous T-cell Lymphoma and Oral Mucositis in head and neck cancer.
2 Minute Company Overview
For more information about Soligenix Inc, please contact Christopher Schraber, CEO at